- Home
- EVRG vs ILMN Comparison
EVRG vs ILMN Comparison
Compare EVRG & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVRG
- ILMN
- Stock Information
- Founded
- EVRG 2017
- ILMN 1998
- Country
- EVRG United States
- ILMN United States
- Employees
- EVRG N/A
- ILMN N/A
- Industry
- EVRG Power Generation
- ILMN Medical Specialities
- Sector
- EVRG Utilities
- ILMN Health Care
- Exchange
- EVRG Nasdaq
- ILMN Nasdaq
- Market Cap
- EVRG 17.9B
- ILMN 15.3B
- IPO Year
- EVRG N/A
- ILMN 2000
- Fundamental
- Price
- EVRG $76.68
- ILMN $123.10
- Analyst Decision
- EVRG Strong Buy
- ILMN Hold
- Analyst Count
- EVRG 10
- ILMN 15
- Target Price
- EVRG $78.35
- ILMN $114.93
- AVG Volume (30 Days)
- EVRG 2.2M
- ILMN 2.0M
- Earning Date
- EVRG 11-06-2025
- ILMN 10-30-2025
- Dividend Yield
- EVRG 3.61%
- ILMN N/A
- EPS Growth
- EVRG N/A
- ILMN N/A
- EPS
- EVRG 3.66
- ILMN 4.46
- Revenue
- EVRG $5,878,800,000.00
- ILMN $4,288,000,000.00
- Revenue This Year
- EVRG $5.19
- ILMN N/A
- Revenue Next Year
- EVRG $3.76
- ILMN $2.22
- P/E Ratio
- EVRG $21.06
- ILMN $27.49
- Revenue Growth
- EVRG 1.75
- ILMN N/A
- 52 Week Low
- EVRG $59.67
- ILMN $68.70
- 52 Week High
- EVRG $79.32
- ILMN $153.06
- Technical
- Relative Strength Index (RSI)
- EVRG 50.16
- ILMN 68.29
- Support Level
- EVRG $74.76
- ILMN $118.50
- Resistance Level
- EVRG $77.36
- ILMN $126.00
- Average True Range (ATR)
- EVRG 1.20
- ILMN 5.00
- MACD
- EVRG -0.32
- ILMN 2.02
- Stochastic Oscillator
- EVRG 47.00
- ILMN 91.61
About EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.